441-02583 (Health)

WHEREAS:

• Brain Cancer in 2023 affected 3,200 Canadians and claimed the lives of 2,500;

• Vorasidenib is a drug that was proven effective at extending the life of brain cancer patients in 2023. Vorasidenib is the first targeted drug developed for people with brain tumors and does not have the same toxic side effects as chemotherapy and radiation. Additionally, Vorasidenib cannot be taken after undergoing chemotherapy and radiation; and

• Vorasidenib is a life-extending medication currently only available in the United States of American and remains inaccessible to Canadians, leaving brain cancer patients in Canada without access to potentially life-extending treatment options.

THEREFORE:

We, the undersigned, citizens of Canada, call upon the Government of Canada to:

1. Improve access to brain cancer treatments by empowering Health Canada to expedite use of patient and laboratory in vitro data to expand access to drugs for brain cancer treatment where clinical trials are not feasible; and

2. Develop a regulatory model that permits the approval of brain cancer treatment medications that can extend patients' lives like Vorsidenib.